Phase I evaluation of NP137

By 18 novembre 2016Actualités

NETRIS Pharma announces the approval of Agence Nationale de Sécurité des Médicaments et produits de santé (ANSM) for the clinical evaluation of NP137, its first humanized monoclonal antibody targeting Netrin-1. This trial will be an open-label, First-In-Human Phase I trial aiming to evaluate safety, pharmacokinetics and clinical activity of NP137 in patients with metastatic and/or advanced solid tumors. Detailed information regarding this trial can be found here: